UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): November 5, 2001
Enchira Biotechnology Corporation
(Exact name of registrant as specified in its charter)
Delaware |
| 0-21130 |
| 04-3078857 |
(State or other jurisdiction of incorporation or organization) |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
|
|
|
|
|
4200 Research Forest Drive | ||||
| ||||
(281) 419-7000 | ||||
Item 5. Other Events
On November 5, 2001, Enchira Biotechnology Corporation (the “Company”) issued a press release announcing that it received a final ruling in its arbitration proceeding with Maxygen Inc. In addition, the press release announced the Company’s new focus on and development of its proprietary Drug Candidate Optimization Platform™ technology and briefly described this new technology. A more complete description of the Drug Candidate Optimization Platform™ and its related technologies may be found on the Company’s recently updated web site at http://www.enchira.com.
The press release is filed as an exhibit to this Current Report on Form 8-K and is incorporated by reference herein.
Item 7. Exhibits
Exhibit 99.1 -- Press Release
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Enchira Biotechnology Corporation
Date: November 6, 2001
By: /s/ Paul G. Brown, III
Paul G. Brown, III
Vice President, Finance and Administration
and Chief Financial Officer
